Lassa epidemiological studies
Expression of interest: epidemiological studies of Lassa fever in West Africa
CEPI plans to provide grants for epidemiological studies of Lassa virus that will inform future trial design, endpoints, and site selection for Lassa-vaccine development.
As part of this “expression of interest” process, CEPI would like to identify research groups that are interested in performing such studies. Such groups can be composed of investigators based anywhere in the world, but the Principal Investigator must be from a Lassa-endemic country, and the consortium must include local co-investigators at each proposed study site.
The expression of interest will serve as a prequalification to apply for funding through a subsequent “request for proposals” on epidemiological studies of Lassa virus.
Points to consider
- Groups are eligible if they have strong local presence in a Lassa-endemic region(s) and previous experience with Lassa field studies.
- All work conducted under this expression of interest and subsequent calls is expected to involve local investigators, and to contribute to strengthening of local clinical-research capacity.
- Applicants selected through this expression of interest will receive “prequalification” to apply for funding through a formal request for proposals (RfP) to be launched at the end of 2018.
- “Prequalified” applicants will be expected to participate in a workshop in Q4 2018 to provide input on harmonising the core study protocol that CEPI will use for the RfP.
Deadline for submission is 12.00 CEST on 30 August 2018. Applicants will be informed of selection results by October 2018.
Responses to CEPI's second call for proposals
On 1st September, CEPI launched its Second Call for Proposals (CfP) on Vaccine platform technologies to promote the objective of developing development of real time response capabilities to novel emerging threats, and immunize at-risk populations against emerging infectious diseases, potentially resulting in great public health impact by rapidly limiting or ending outbreaks.
In response to this Call for Proposals, the Secretariat received over 35 applications by the deadline of 17 October, with a broad diversity displayed in the vaccine platform technologies being proposed, including both novel concepts and established technologies. All eligible submissions are now being evaluated, and shortlisted applicants will be notified in December to submit detailed proposals in early 2018.
Similar to our previous call, applicants and their partners are from North America, South America, Europe, Africa, Asia and Australia, representing academic institutions, biotechs, large pharmaceutical companies and Product Development Partnerships.More information
Work on Ebola
The "Ebola vaccines regulatory scientific meeting" enabled us to look into future regulatory scientific research areas which will be further refined and taken forward in smaller task forces. Updates on how we will proceed the work on Ebola will be published on our website and Newsletter.
The summary report can be found here.